Disease · MONDO_0001126

gastric ulcer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastric ulcer. Diseases, record MONDO_0001126. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001126

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastric ulcer; Open Targets
Open Targets ID: MONDO_0001126; Open Targets
Other names: gastric ulcer (disease), peptic ulcer disease of stomach, stomach peptic ulcer, stomach peptic ulcer disease; Open Targets
Disease Ontology: DOID:10808; Disease Ontology
MeSH: D013276; MeSH
NCI Thesaurus: C3388; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 27 drugs, from DailyMed and PMDA; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VONOPRAZAN FUMARATE	CHEMBL2064032	Small molecule	Approval	PMDA	6	4	4	Drugs and targets
OMEPRAZOLE	CHEMBL1503	Small molecule	Approval	DailyMed	77	1	1	Drugs and targets
LANSOPRAZOLE	CHEMBL480	Small molecule	Approval	DailyMed and PMDA	14	1	1	Drugs and targets
FAMOTIDINE	CHEMBL902	Small molecule	Approval	DailyMed	5	1	1	Drugs and targets
ESOMEPRAZOLE MAGNESIUM	CHEMBL5314366	Small molecule	Approval	DailyMed and PMDA	17	0	0	Drugs and targets
ESOMEPRAZOLE STRONTIUM	CHEMBL2146140	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
RABEPRAZOLE SODIUM	CHEMBL1200930	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
RANITIDINE HYDROCHLORIDE	CHEMBL2110372	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	12	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	12	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
HRH2	Histamine H2 receptor	3	Histamine H2 receptor antagonist	Approval	https://conductscience.org/library/genes/3274	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
ADRB1	Adrenergic receptor beta	1	Adrenergic receptor beta antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor beta	1	Adrenergic receptor beta antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03214952	Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"		3,183	2019-12-12	Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis	VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT03214094	Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"		1,119	2020-03-11	Gastric or Duodenal Ulcers	VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT03219723	Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"		560	2019-03-22	Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other	AMOXICILLIN, CLARITHROMYCIN, METRONIDAZOLE, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT00401752	Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer	Phase 3	397	2010-07-08	Gastric Ulcer	ESOMEPRAZOLE, RANITIDINE	Its record names the disease	ClinicalTrials.gov
NCT03050307	Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection	Phase 3	234	2021-06-18	Gastric Ulcer	VONOPRAZAN FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00511745	Safety of Rabeprazole in Patients Under Multiple Treatments		2,157		Gastroesophageal Reflux, Gastric Ulcer	AMOXICILLIN, CLARITHROMYCIN, RABEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01505127	Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori	Phase 3	650		H. Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, VONOPRAZAN FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT01452711	Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer	Phase 3	482		Gastric Ulcer	LANSOPRAZOLE, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT00633412	A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only	Phase 3	400		NSAID Associated Gastric Ulcers	ESOMEPRAZOLE, RANITIDINE	Its record names the disease	ClinicalTrials.gov
NCT00633672	A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued	Phase 3	400		NSAID Associated Gastric Ulcers	ESOMEPRAZOLE, RANITIDINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TAK-438 20 mg vs Lansoprazole 30 mg: deaths from any cause	0 of 115	0 of 119	234	NCT03050307	Trial comparisons
TAK-438 20 mg vs Lansoprazole 30 mg: serious adverse events	3 of 115	2 of 119	234	NCT03050307	Trial comparisons
Esomeprazole vs Ranitidine: serious adverse events	2 of 107	2 of 110	217	NCT00401752	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41028410	DERIVED	1	PubMed
39085080	DERIVED	1	PubMed
27891632	DERIVED	1	PubMed
26935876	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001126

GET https://conductscience.org/api/diseases/v1/MONDO_0001126/drugs?page=2

API reference For AI assistants